Kato T, Goshima T, Nakajima N, Kaku H, Arimoto Y, Hayashi F
Acta Paediatr Jpn. 1989 Dec;31(6):698-701. doi: 10.1111/j.1442-200x.1989.tb01382.x.
To evaluate the vaccine efficacy of an acellular pertussis vaccine which has been in clinical use in Japan since 1981, a retrospective study was performed by a questionnaire survey of secondary pertussis attacks through family contact in 146 children with pertussis diagnosed in the period from January 1981 through May 1988. In this study, acellular vaccine made by Takeda Pharmaceutical Company, which contains a high level of FHA (filamentous hemagglutinin), a low level of PT (pertussis toxin) and a small amount of agglutinogen, was evaluated. Secondary pertussis attacks through family contact were found in 17 of 29 siblings (58.6%) not immunized with pertussis vaccine. On the other hand, 27 siblings immunized with Takeda's acellular vaccine were exposed to pertussis through family contact and a secondary attack was seen in only one of them (3.7%). The present study revealed an efficacy rate of 93.7% for Takeda's acellular pertussis vaccine.
为评估1981年起在日本临床使用的无细胞百日咳疫苗的疫苗效力，通过对1981年1月至1988年5月期间确诊的146例百日咳患儿进行问卷调查，对家庭接触引发的二次百日咳发作情况进行了回顾性研究。在本研究中，对武田制药公司生产的无细胞疫苗进行了评估，该疫苗含有高水平的丝状血凝素（FHA）、低水平的百日咳毒素（PT）和少量凝集原。在29名未接种百日咳疫苗的兄弟姐妹中，有17名（58.6%）通过家庭接触发生了二次百日咳发作。另一方面，27名接种了武田无细胞疫苗的兄弟姐妹通过家庭接触暴露于百日咳，其中只有1人（3.7%）出现了二次发作。本研究显示，武田无细胞百日咳疫苗的效力为93.7%。
